IP Library Granted Patent US 12,466,865
Granted Patent B2
US 12,466,865 · App. 17/415,156 · Granted Nov 11, 2025

Method and kit for treating a neurodegenerative disease

Inventors: Jeffrey A. Loeb (Chicago, IL); Fei Song (Troy, MI)
Assignee: The Board of Trustees of the University of Illinois
C07K14/4756A61K45/06A61P25/16A61P25/28C07K14/82A61K38/00C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,865
App. No.
17/415,156
Granted
Nov 11, 2025
Kind
B2
Abstract

A method and kit for treating a neurodegenerative disease or central nervous system disorder in a subject using a GlyB4 fusion protein is provided, as is a kit containing the same.

Claims (7)

1 . A method of reducing amyloid β plaque formation in a subject comprising administering to the subject in need of treatment an effective amount of GlyB4 fusion protein consisting of SEQ ID NO: 1, wherein the GlyB4 fusion protein penetrates the central nervous system thereby reducing amyloid β plaque formation.

2 . The method of claim 1 , wherein comprises intraventricular, intrathecal, administrating subcutaneous or intravenous delivery of the GlyB4 fusion protein to the subject.

3 . A method of treating Alzheimer's disease in a subject comprising administering to the subject in need of treatment an effective amount of a composition formulated for intraventricular or intrathecal delivery of a GlyB4 fusion protein consisting of SEQ ID NO: 1, wherein said composition penetrates the brain and blocks brain inflammation and/or reduces amyloid β plaque formation thereby treating the subject's Alzheimer's disease.

4 . The method of claim 3 , wherein intraventricular delivery is via intracerebroventricular or intrathecal implantation.

5 . A method of reducing brain inflammation in a subject comprising administering to the subject in need of treatment an effective amount of GlyB4 fusion protein consisting of SEQ ID NO:1, wherein the GlyB4 fusion protein penetrates the central nervous system thereby reducing brain inflammation in the subject.

6 . The method of claim 5 , wherein the subject has Alzheimer's disease.

7 . The method of claim 5 , wherein administrating comprises intraventricular, intrathecal, subcutaneous or intravenous delivery of the GlyB4 fusion protein to the subject.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 26, 2023
From: UNIVERSITY OF ILLINOIS AT CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066128/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2021
From: LOEB, JEFFREY A.; SONG, FEI
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 056575/0787 →
Continuity (2)
Provisional Application 62787852 · Jan 3, 2019
Related Publication 20220041673A1 · Feb 10, 2022
References Cited (9)
US 20050107601A1 · Loeb · 2005 [cited by applicant]
US 20070081992A1 · Pardridge et al. · 2007 [cited by applicant]
US 20080207484A1 · Loeb · 2008 [cited by applicant]
WO 2003012045A2 · 2003 [cited by applicant]
WO 2006017184A2 · 2006 [cited by applicant]
Yoav Ben-Shlomo, et al, Parkinson's Disease 1, The epidemiology of Parkinson's disease, Lancet 2024; 403: 283-92 (Year: 2024). [cited by examiner]
International Preliminary Report on Patentability in PCT/US2020/012025 dated Jun. 16, 2021. [cited by applicant]
International Search Report and Written Opinion in PCT/US2020/012025 dated Mar. 17, 2020. [cited by applicant]
Ma, Z. et al. (2009) “Targeting Human Epidermal Growth Factor Receptor Signaling with the Neuregulin's Heparin-binding Domain,” The Journal of Biological Chemistry 284(46):32108-32115. [cited by applicant]